CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
4 research outputs found
A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
Author
Alexander Zukiwski
Alice Susannah Bexon
+13Â more
Anas Gazzah
Andrea Varga
Catherine Lhomme
Erard M. Gilles
Eric Leblanc
Francois Marc Lokiec
Jacques Bonneterre
Joseph Bisaha
Keyvan Rezai
Marc Espie
Paul H. Cottu
Sylvie Giacchetti
Veronique Dieras
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).
Author
Alexander Zukiwski
Alice Susannah Bexon
+12Â more
Andre Paquin
Daniel Nava Rodrigues
Francois Marc Lokiec
Gerhardt Attard
Joaquin Mateo
Johann Sebastian De Bono
Joseph Bisaha
Nina Tunariu
Penelope Flohr
Raquel Perez Lopez
Ruth Riisnaes
Stefan Proniuk
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.
Author
Alexander Zukiwski
Alice Susannah Bexon
+14Â more
Andrea Varga
Antoine Italiano
Anuradha Jayaram
Charles Barranco
Erard M. Gilles
Fanny Bret
Francois Marc Lokiec
Gerhardt Attard
Jacques Bonneterre
Keyvan Rezai
Mario Campone
Paul H. Cottu
Samuel Huguet
Stefan Proniuk
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Safety and pharmacokinetic (PK) results from phase 1 of an ongoing phase 1-2 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
Author
Alexander Zukiwski
Alexandra Leary
+15Â more
Alice Susannah Bexon
Andrea Varga
Anne Floquet
Anne Lesoin
Antoine Italiano
Catherine Lhommé
Dominique Berton-Rigaud
Erard M. Gilles
Francois Marc Lokiec
Jacques Bonneterre
Joseph Bisaha
Keyvan Rezai
Marie-Paule Sablin
Mario Campone
Paul H. Cottu
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref